Differentiating in HPV

Roche hopes data from the pivotal trial of its cobas HPV Test will result in a change in cervical cancer screening guidelines that would drive use of the molecular diagnostic. But ultimately, uptake will likely depend on the prices of the test and related instrumentation compared to competitor prices.

In April, cobas became the fourth FDA-approved DNA test to detect HPV. But it is the first DNA test that specifically identifies the presence of HPV 16 and 18 - the most oncogenic genotypes - concurrently with testing for other high-risk strains of the virus...